Science Explorer Back to mapMap
Discussion
Company · Santa Monica · United States

Max Biopharma (United States)

maxbiopharma.comROR OpenAlex
Research works
15
▲ 104% vs 2018-21
Citations
163
11.0 per fractional work
Top-10% rate
6.2%
all institutions 10.0%
Open access
64%
world 40%
International
26%
world 18%
Max Biopharma (United States)

Not ranked overall: Max Biopharma (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Max Biopharma (United States) work in?

In all years, 44% of research at Max Biopharma (United States) is in Life Sciences, 44% in Health Sciences. Its largest fields are Medicine (41%), Biochemistry, Genetics and Molecular Biology (40%), Engineering (5%). It does 1.8× the world's share of Life Sciences.

Life Sciences: 6 fractional works · 43.7% of its workBiochemistry, Genetics and Molecular Biology: 6 fractional works · 40.4% of its workMolecular Biology: 4 fractional works · 25.8% of its workGenetics: 1 fractional works · 8.4% of its workCancer Research: 0 fractional works · 2.9% of its workBiochemistry: 0 fractional works · 2.2% of its workMolecular Medicine: 0 fractional works · 0.7% of its workCell Biology: 0 fractional works · 0.3% of its workImmunology and Microbiology: 0 fractional works · 1.6% of its workImmunology: 0 fractional works · 1.3% of its workVirology: 0 fractional works · 0.3% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.5% of its workPharmacology: 0 fractional works · 1.5% of its workAgricultural and Biological Sciences: 0 fractional works · 0.2% of its workFood Science: 0 fractional works · 0.2% of its workHealth Sciences: 6 fractional works · 43.7% of its workMedicine: 6 fractional works · 41.3% of its workOncology: 1 fractional works · 9.3% of its workPulmonary and Respiratory Medicine: 1 fractional works · 4.9% of its workInfectious Diseases: 1 fractional works · 4.9% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 4.5% of its workSurgery: 1 fractional works · 4.5% of its workEpidemiology: 1 fractional works · 4.2% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 2.2% of its workGenetics: 0 fractional works · 1.4% of its workHepatology: 0 fractional works · 1.4% of its workPathology and Forensic Medicine: 0 fractional works · 1.4% of its workPhysiology: 0 fractional works · 1.1% of its workPharmacology: 0 fractional works · 0.7% of its workHematology: 0 fractional works · 0.5% of its workHealth Professions: 0 fractional works · 2.2% of its workGeneral Health Professions: 0 fractional works · 2.2% of its workNursing: 0 fractional works · 0.2% of its workNutrition and Dietetics: 0 fractional works · 0.2% of its workPhysical Sciences: 1 fractional works · 10.0% of its workEngineering: 1 fractional works · 4.5% of its workElectrical and Electronic Engineering: 0 fractional works · 2.2% of its workControl and Systems Engineering: 0 fractional works · 1.5% of its workBiomedical Engineering: 0 fractional works · 0.7% of its workSmaller subfields together: 0 fractional works · 0.1% of its workMaterials Science: 0 fractional works · 2.5% of its workBiomaterials: 0 fractional works · 1.5% of its workElectronic, Optical and Magnetic Materials: 0 fractional works · 0.7% of its workMaterials Chemistry: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workComputer Science: 0 fractional works · 2.2% of its workComputational Theory and Mathematics: 0 fractional works · 2.2% of its workChemistry: 0 fractional works · 0.7% of its workOrganic Chemistry: 0 fractional works · 0.7% of its workSocial Sciences: 0 fractional works · 2.6% of its workEconomics, Econometrics and Finance: 0 fractional works · 2.6% of its workEconomics and Econometrics: 0 fractional works · 2.6% of its workALL ITS WORKMax Biopharma(United States)15fractional works, all years
Life Sciences44%Physical Sciences10%Health Sciences44%Social Sciences3%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology640.4%
    2. Immunology and Microbiology01.6%
    3. Pharmacology, Toxicology and Pharmaceutics01.5%
    4. Agricultural and Biological Sciences00.2%
    1. Medicine641.3%
    2. Health Professions02.2%
    3. Nursing00.2%
    1. Engineering14.5%
    2. Materials Science02.5%
    3. Computer Science02.2%
    4. Chemistry00.7%
    1. Economics, Econometrics and Finance02.6%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 7.02× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 2.92× its world share, 0 worksImmunology and Micro…Computer Science: 0.70× its world share, 0 worksComputer ScienceEngineering: 0.12× its world share, 0 worksEngineeringMaterials Science: 0.52× its world share, 0 worksMaterials ScienceMedicine: 2.59× its world share, 3 worksMedicineEconomics, Econometrics and Finance: 0.36× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 7.0×. Every wedge is a field page.

All 7 fields, with their numbers
  1. Biochemistry, Genetics and Molecular Biology7.02×2 works
  2. Immunology and Microbiology2.92×0 works
  3. Medicine2.59×3 works
  4. Computer Science0.70×0 works
  5. Materials Science0.52×0 works
  6. Economics, Econometrics and Finance0.36×0 works
  7. Engineering0.12×0 works

Who are the top researchers at Max Biopharma (United States)?

Ranked on the quality score, Frank Stappenbeck lead among researchers whose main affiliation is Max Biopharma (United States).

  1. 1 Frank Stappenbeck United States · #4,760,820 worldwide 607 citations · 39 works
All ranked researchers at Max Biopharma (United States)

What are the most cited papers from Max Biopharma (United States)?

The most cited paper from Max Biopharma (United States) is "State-of-the-Art of Eggshell Waste in Materials Science: Recent Advances in Catalysis, Pharmaceutical Applications, and Mechanochemistry" (Matěj Baláž, E.V. Boldyreva, Д. С. Рыбин et al., 2021), with 128 citations. Next come "Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo" (89) and "Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin" (61).

Most cited papers
#PaperReleasedCitations
1 State-of-the-Art of Eggshell Waste in Materials Science: Recent Advances in Catalysis, Pharmaceutical Applications, and Mechanochemistry Matěj Baláž, E.V. Boldyreva, Д. С. Рыбин et al. · Frontiers in Bioengineering and Biotechnology Open access 27 Jan 2021 128
2 Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo George K. Dresser, Vincent J. Wacher, Susan Wong et al. · Clinical Pharmacology & Therapeutics Sep 2002 89
3 Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin Abraham H. Abouzeid, Niravkumar R. Patel, Ilya M. Rachman et al. · Journal of drug targeting 7 Oct 2013 61
4 Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells Shengjiang Liu, Jinzhong Li, Sameera Peraramelli et al. · Molecular Therapy Open access 20 Nov 2023 47
5 Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro Hirofumi Ohashi, Feng Wang, Frank Stappenbeck et al. · International Journal of Molecular Sciences Open access 19 Mar 2021 26
All 32 most cited papers, with filters and sorting

Which research topics does Max Biopharma (United States) publish most on?

By volume in 2022-now: Hedgehog Signaling Pathway Studies, Viral Infectious Diseases and Gene Expression in Insects, Virus-based gene therapy research and Liver Disease Diagnosis and Treatment.

Hedgehog Signaling Pathw…0Hedgehog Signaling Pathway Studies: 0 fractional worksViral Infectious Disease…0Viral Infectious Diseases and Gene Expression in Insects: 0 fractional worksVirus-based gene therapy research: 0 fractional worksLiver Disease Diagnosis and Treatment: 0 fractional worksSARS-CoV-2 and COVID-19 Research: 0 fractional worksConnective Tissue Growth Factor Research: 0 fractional worksCAR-T cell therapy research: 0 fractional worksComputational Drug Disco…0Computational Drug Discovery Methods: 0 fractional worksInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis: 0 fractional worksCOVID-19 Clinical Research Studies: 0 fractional works
Molecular BiologyGeneticsEpidemiologyInfectious Diseases3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Hedgehog Signaling Pathway Studies Molecular Biology 0 works
  2. 2 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
  3. 3 Virus-based gene therapy research Genetics 0 works
  4. 4 Liver Disease Diagnosis and Treatment Epidemiology 0 works
  5. 5 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works
  6. 6 Connective Tissue Growth Factor Research Molecular Biology 0 works
  7. 7 CAR-T cell therapy research Oncology 0 works
  8. 8 Computational Drug Discovery Methods Computational Theory and Mathematics 0 works
  9. 9 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 0 works
  10. 10 COVID-19 Clinical Research Studies Infectious Diseases 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available64.4%not open35.6%

World: 40% of research is openly available.

with international co-authors26.2%domestic only73.8%

World: 18% is written across borders.

How has Max Biopharma (United States)'s research output changed?

Output in 2022-2025 was 104% higher than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Max Biopharma (United States) as a percentage of every work published that year, 0.000041% in 2024.

still counting0.000050%0.00010%0.00015%Max Biopharma (United States)0.000026% in 2025200020102020

Fractional works of Max Biopharma (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Santa Monica

All research institutions in Santa Monica

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Max Biopharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.